Metro Brands

India | Footwear | Result Update

Delayed expansion to impact growth

Metro Brands' (METROBRA IN) Q3FY25 revenue and EBITDA were lower by 3.0% and 2.3%, respectively versus our estimates. However, PAT was 21.9% lower on account of one-time tax adjustment for the *Fila* business. In Q3, demand recovered, driven by the festival and wedding seasons, following a subdued H1FY25. Store opening was below our estimates and guidance. METROBRA retained its guidance of 225 new store openings in FY25-26, implying higher store openings in FY26. We pare down our earnings estimates by 20.6% for FY25E, 19.9% for FY26E and 22.5% for FY27E, taking into consideration postponement of store additions, leading to delayed volume strength and increased other income. Thus, we also lower our TP to INR 1,457 from INR 1,873, based on 75x FY27E P/E. We maintain **Buy**.

Uplift from festival season moderates; store additions lag: Q3 revenue grew 10.6% YoY, led by implied volume growth of 10.6% as average selling price (ASP) was flat YoY. Revenue per sqft fell 1.0% YoY to INR 5,150 – Demand was subdued for the period other than festival and wedding seasons. We expect a revenue CAGR of 12.7% in FY24-27E, driven by new store openings, integration of brands and premiumization strategy. METROBRA added 24 stores in Q3, offset by two stores closing, resulting in 8.4% YoY store growth, taking the total to 895 in Q3FY25. Gross store additions stood at 64 and net additions at 57 in 9MFY25. METROBRA pared its store opening guidance of 100 stores in FY25, but retained its guidance to open 225 stores by FY26. We assume 205 store additions in the same period. We expect store network to post a CAGR of 10.7% in FY24-27E to reach 1,134 stores by FY27E. With completion of *Fila* inventory liquidation and compliance with BIS norms, we expect store expansion for *Fila* and *Footlocker* to gain traction in H2FY26.

Steady margin outlook maintained: Q3 gross margin declined 125bps YoY to 58.6% from 59.9% in Q3FY24, led by higher discounting on account of *Fila* inventory liquidation. EBITDA margin expanded 70bps YoY to 32.0% from 31.3% in Q3FY24, led by lower other expenses. We expect EBITDA margin to touch 30.8% by FY27E, led by premiumization and operating leverage. METROBRA retained its guidance of ~30%+ EBITDA margin in FY25. PAT declined 3.7% YoY to INR 951mn, hit by one-time charge of INR 250mn related to the reconciliation of tax balances for the *Fila* business and supported by higher other income. Adjusting for this, PAT would have been INR 1,201mn, largely inline with our estimates.

Maintain Buy with a lower TP of INR 1,457: We expect a revenue CAGR of 12.2%, an EBITDA CAGR of 14.1% and an earnings CAGR of 8.7% in FY24-27E. We maintain our stance that METROBRA is well positioned to leverage the improvement in demand, led by strong brand positioning and recall, continued store expansion and strong FCF generation. We lower our TP to INR 1,457 from INR 1,873, based on 75x (maintained) FY27E P/E. Risks to our call are lower-than-expected new store openings and extended subdued demand trend.

Key financials

YE March	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR mn)	21,271	23,567	25,086	28,853	33,736
YoY (%)	58.4	10.8	6.4	15.0	16.9
EBITDA (INR mn)	6,787	6,996	7,551	8,829	10,391
EBITDA margin (%)	31.9	29.7	30.1	30.6	30.8
Adj PAT (INR mn)	3,615	4,125	3,557	4,369	5,293
YoY (%)	70.8	14.1	-13.8	22.8	21.2
Fully DEPS (INR)	13.3	15.2	13.1	16.1	19.5
RoE (%)	23.0	21.8	16.5	17.6	18.4
RoCE (%)	23.5	22.2	16.3	17.7	18.3
P/E (x)	90.1	79.0	91.6	74.6	61.6
EV/EBITDA (x)	48.0	46.5	42.6	36.1	30.3

Note: pricing as on 17 January 2025; Source: Company, Elara Securities Estimate

19 January 2025


Rating: Buy
Target Price: INR 1,457
Upside: 21%
CMP: INR 1, 199
As on 17 January 2025

Kev data

METROBRA IN
METB.NS
272
326/3,767
327/3,780
140/2
1,430/990
28

Note: as on 17 January 2025; Source: Bloomberg

Price chart



Source:	Bloomberg	
---------	-----------	--

Shareholding (%)	Q3 FY24	Q4 FY24	Q1 FY25	Q2 FY25
Promoter	74.2	74.2	74.2	72.0
% Pledged	-	-	-	-
FII	2.7	2.7	3.1	3.4
DII	6.0	6.0	5.6	7.0
Others	17.2	17.1	17.2	17.7
Source: BSE				

Price performance (%)	ЗM	6M	12M
Nifty	(6.2)	(5.7)	7.6
Metro Brands	(5.4)	(10.5)	(2.3)
NSE Mid-cap	(6.6)	(5.3)	15.8
NSE Small-cap	(7.3)	(7.3)	15.1

Prerna Jhunjhunwala Textiles, Retail, +91 22 6164 8519 prerna.jhunjhunwala@elaracapital.ccc

Associates Tejal Nagmoti Gnyan Thaker



Elara Securities (India) Private Limited



Financials (YE March)

income Statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Revenues	21,271	23,567	25,086	28,853	33,736
EBITDA	6,787	6,996	7,551	8,829	10,391
Add:- Non operating Income	544	708	953	1,154	1,349
DPBIDTA	7,332	7,704	8,504	9,983	11,740
ess :- Depreciation & Amortization	1,810	2,291	2,551	2,956	3,364
BIT	5,521	5,413	5,953	7,027	8,376
.ess:- Interest Expenses	631	789	909	1,203	1,320
РВТ	4,891	4,624	5,045	5,824	7,056
Less :- Taxes	1,257	499	1,488	1,456	1,764
Less :- Minority Interest / JV	39	30	33	36	39
Add :- Associate profits	20	30	33	37	40
Adjusted PAT	3,615	4,125	3,557	4,369	5,293
Reported PAT	3,615	4,125	3,557	4,369	5,293
Balance Sheet (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Share Capital	1,359	1,360	1,360	1,360	1,360
Reserves	14,382	17,571	20,239	23,515	27,484
Other LT Liabilities	8,173	9,537	10,332	12,060	13,155
Fotal Liabilities	23,914	28,468	31,931	36,934	41,998
Gross Block	4,539	5,331	5,901	6,819	7,599
Less:- Accumulated Depreciation	1,563	1,829	2,223	2,686	3,207
Net Block	2,976	3,502	3,678	4,133	4,392
Add:- Capital work in progress	171	73	80	88	97
Dther LT Assets	10,889	13,036	13,384	14,459	14,684
Net Working Capital	9,560	11,378	10,706	11,098	11,790
Cash and cash equivalent	318	479	4,082	7,156	11,035
Fotal Assets	23,914	28,468	31,931	36,934	41,998
Cash Flow Statement (INR mn)	FY23	FY24	FY25E	FY26E	FY27E
Cash profit adjusted for non cash items	6,945	7,230	7,551	7,551	8,829
		7,200	7,001	7,001	0,027
\dd/Less : Working Capital Changes	(3.139)	(1.330)	(1.114)	(1.114)	(2.215)
Add/Less : Working Capital Changes	(3,139)	(1,330)	(1,114)	(1,114)	
Dperating Cash Flow	3,807	5,901	6,436	6,614	7,662
Operating Cash Flow Less:- Capex	3,807 (996)	5,901 (1,161)	6,436 (592)	6,614 (943)	7,662 (807)
Deprating Cash Flow Less:- Capex Free Cash Flow	3,807 (996) 2,810	5,901 (1,161) 4,740	6,436 (592) 5,844	6,614 (943) 5,671	7,662 (807) 6,855
Deprating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow	3,807 (996) 2,810 (515)	5,901 (1,161) 4,740 (2,513)	6,436 (592) 5,844 328	6,614 (943) 5,671 175	7,662 (807) 6,855 502
Deprating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow	3,807 (996) 2,810 (515) (3,588)	5,901 (1,161) 4,740 (2,513) (3,227)	6,436 (592) 5,844 328 (3,161)	6,614 (943) 5,671 175 (3,715)	7,662 (807) 6,855 502 (4,285)
Operating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Vet change in Cash	3,807 (996) 2,810 (515) (3,588) (297)	5,901 (1,161) 4,740 (2,513) (3,227) 161	6,436 (592) 5,844 328 (3,161) 3,603	6,614 (943) 5,671 175 (3,715) 3,074	7,662 (807) 6,855 502 (4,285) 3,880
Operating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis	3,807 (996) 2,810 (515) (3,588)	5,901 (1,161) 4,740 (2,513) (3,227)	6,436 (592) 5,844 328 (3,161)	6,614 (943) 5,671 175 (3,715)	7,662 (807) 6,855 502 (4,285) 3,880
Deperating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Vet change in Cash Ratio Analysis Income Statement Ratios (%)	3,807 (996) 2,810 (515) (3,588) (297) FY23	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24	6,436 (592) 5,844 328 (3,161) 3,603 FY25E	6,614 (943) 5,671 175 (3,715) 3,074 FY26E	7,662 (807) 6,855 502 (4,285) 3,880 FY27E
Deperating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.9
Deperating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7,9	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7
Deperating Cash Flow Less:- Capex Free Cash Flow Investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8)	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth EBITDA Growth EBITDA Margin	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.9 17.7 21.2 30.8
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth EBITDA Growth EBITDA Margin Vet Margin	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8)	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.9 17.7 21.2 30.8
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.8 15.7
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02)	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03)	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19)	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29)	7,662 (807) 6,855 502 (4,285 3,880 FY27E 16.5 17.7 21.2 30.8 15.7
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Vet change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.8 15.7 (0.38) 18.4
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Vet change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth DPAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02)	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03)	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19)	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29)	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.8 15.7 (0.38) 18.4
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Vet change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7	7,662 (807) 6,855 3,880 FY27E 166.9 17.7 21.2 30.8 15.7 (0.38) 18.4 18.3
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Vet change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Vet Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 13.1	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 16.1	7,662 (807) 6,855 3,880 FY27E 166.9 17.7 21.2 30.6 15.7 (0.38) 18.4 18.3
Deperating Cash Flow Less:- Capex Free Cash Flow Linvesting Cash Flow Linvesting Cash Flow Vet change in Cash Ratio Analysis Lincome Statement Ratios (%) Revenue Growth EBITDA Growth EBITDA Growth PAT Growth EBITDA Margin Return & Liquidity Ratios Net Debt/Equity (x) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 31.3 31.9	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 13.1 (13.8)	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 16.1 22.8	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.6 15.7 (0.38 18.4 18.3 19.5 21.2
Deperating Cash Flow Less:- Capex Free Cash Flow Linvesting Cash Flow Linvesting Cash Flow Second Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%) DPS (INR/Share)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 13.1 (13.8) 3.3	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.8 15.7 (0.38) 18.4 18.3 19.5 21.2 21.2
Deperating Cash Flow Less:- Capex Free Cash Flow Linvesting Cash Flow Linvesting Cash Flow Vet change in Cash Ratio Analysis Ratio Anal	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2 90.1	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2 79.0	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 13.1 (13.8) 3.3 91.6	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0 74.6	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.6.5 17.7 21.2 30.8 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 19.5 21.2 21.2 21.2 21.2 21.2
Deperating Cash Flow Less:- Capex Free Cash Flow Linvesting Cash Flow Linuesting Cash Flow Vet change in Cash Ratio Analysis Lincome Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%) DPS (INR/Share) P/E Ratio (x) EV/EBITDA (x)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 13.1 (13.8) 3.3	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0 74.6 36.1	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.5 17.7 21.2 30.6 15.7 15.7 15.7 21.2 30.6 18.4 18.3 19.5 21.2 21.2 4.5 21.2 21.2 21.2
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%) DPS (INR/Share) P/E Ratio (x) EV/EBITDA (x) EV/Sales (x)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2 90.1 48.0 15.3	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2 79.0 46.5 13.8	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 (0.19) 16.5 16.3 3.3 91.6 42.6 12.8	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0 74.6 36.1 11.1	7,662 (807) 6,855 502 (4,285 3,880 FY27E 16.9 17.7 21.2 30.8 (0.38 18.4 18.3 (0.38 18.4 19.5 21.2 21.2 30.8 (0.38 18.4 18.3 19.5 21.2 21.2 21.2 21.2 30.8 (0.38 18.4 18.5 21.2 5 21.2 5 30.8 5 10 5 5 21.2 5 5 21.2 5 5 5 21.2 5 5 5 21.2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Deperating Cash Flow Less:- Capex Free Cash Flow Linvesting Cash Flow Linuesting Cash Flow Vet change in Cash Ratio Analysis Lincome Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%) DPS (INR/Share) P/E Ratio (x) EV/EBITDA (x)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2 90.1 48.0	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2 79.0 46.5	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 (0.19) 16.5 16.3 3.3 91.6 42.6	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0 74.6 36.1	7,662 (807) 6,855 502 (4,285) 3,880 FY27E 166.9 17.7 21.2 30.8 15.7 (0.38) 18.4 18.3 19.5 21.2 21.2 4.9 61.6 30.3
Deperating Cash Flow Less:- Capex Free Cash Flow investing Cash Flow Financing Cash Flow Net change in Cash Ratio Analysis Income Statement Ratios (%) Revenue Growth EBITDA Growth PAT Growth EBITDA Margin Net Margin Return & Liquidity Ratios Net Debt/Equity (x) ROE (%) ROCE (%) Post tax Per Share data & Valuation Ratios Diluted EPS (INR/Share) EPS Growth (%) DPS (INR/Share) P/E Ratio (x) EV/EBITDA (x) EV/Sales (x)	3,807 (996) 2,810 (515) (3,588) (297) FY23 58.4 65.9 70.8 31.9 17.0 (0.02) 23.0 23.5 13.3 70.7 3.2 90.1 48.0 15.3	5,901 (1,161) 4,740 (2,513) (3,227) 161 FY24 10.8 3.1 14.1 29.7 17.5 (0.03) 21.8 22.2 15.2 14.1 4.2 79.0 46.5 13.8	6,436 (592) 5,844 328 (3,161) 3,603 FY25E 6.4 7.9 (13.8) 30.1 14.2 (0.19) 16.5 16.3 (0.19) 16.5 16.3 3.3 91.6 42.6 12.8	6,614 (943) 5,671 175 (3,715) 3,074 FY26E 15.0 16.9 22.8 30.6 15.1 (0.29) 17.6 17.7 (0.29) 17.6 17.7 16.1 22.8 4.0 74.6 36.1 11.1	(2,215) 7,662 (807) 6,855 502 (4,285) 3,880 FY27E 16.9 17.7 21.2 30.8 15.7 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 18.3 (0.38) 18.4 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 19.5 (0.38) 10.5 (0.5)(0.5)(0.5)(0.5)

We expect a revenue CAGR of 12.7% in FY24-27E, led by store expansion and premiumization

Note: pricing as on 17 January 2025; Source: Company, Elara Securities Estimate

Margin to remain above 30%

Quarterly financials

INR mn	Q3FY25	Q3FY24	YoY (%)	Q2FY25	QoQ (%)	Q3FY25E	Act Vs Est
Revenues	7,031	6,355	10.6	5,855	20.1	7,245	(3.0)
Raw material	2,908	2,549	14.1	2,633	10.5	2,927	(0.6)
Gross profit	4,123	3,806	8.3	3,222	28.0	4,318	(4.5)
Gross margins (%)	58.6	59.9	(125) bp	55.0	361 bp	59.60	(96) bp
Staff costs	634	604	5.0	597	6.2	652	(2.8)
Other expenses	1,239	1,213	2.2	1,077	15.0	1,362	(9.1)
Total expenditure	4,781	4,365	9.5	4,306	11.0	4,941	(3.2)
EBITDA	2,250	1,990	13.1	1,548	45.4	2,304	(2.3)
EBITDAM (%)	32.0	31.3	70 bp	26.4	556 bp	31.80	21 bp
Depreciation	655	586	11.7	624	4.9	695	(5.8)
Interest	235	204	15.2	218	7.6	196	20.0
Other income	232	160	45.5	234	-0.7	145	60.1
РВТ	1,593	1,359	17.2	939	69.5	1,558	2.3
Tax	649	379	71.4	225	188.6	343	89.3
Share in profit in JV	7	7	(4.2)	3	122.6	3	112.0
Net profit	951	988	(3.7)	718	32.5	1,218	(21.9)
EPS (INR)	3.5	3.6	(3.7)	2.6	32.5	4.5	(21.9)

Source: Company, Elara Securities Estimate

Analyst call – Highlights

Demand scenario and operational highlights

- In Q3FY25, demand was robust in October and November but was slightly hit in December, as other brands and retailers opted for early discounting while METROBRA did not opt for this.
 - METROBRA maintained its guidance for gross margin at +55% and EBITDA margin at 30%.
- METROBRA's e-commerce contribution rose to 11% in 9MFY25, also impacting overall gross margin.
- METROBRA tested the quick commerce channel in select markets, with initial results positive.
- Average selling price (ASP) was stable at INR 1,500 due to increasing sales of accessories, which are lower priced then footwear. So, increasing ASP in footwear did not reflect in the overall ASP.
- New brands, *Fila, Footlocker* and *New Era*, are currently in incubation stage and are expected to ramp-up in the next 2-3 years.

Store network

- METROBRA pared down its store opening guidance of >100 stores in FY25. However, it retained its guidance to open 225 stores cumulatively in FY25 and FY26.
- METROBRA has an aggressive store expansion target to add 140-145 stores in FY26, with addition of 24-40 cities by FY26.
- Mall opening delays and high demand for retail space have pushed some store openings to Q1FY26.
- *Footlocker* has three stores in the pipeline, expected to be rolled out in the next 6-9 months, contingent to BIS approvals.

Performance marginally lower than expectations, led by slight recovery in demand, lower net store additions, while margin took a hit due to liquidation of *Fila* inventory, partially offset by lower other expenses and higher other income.



Fila – Update

- Inventory liquidation was completed in Q3FY25, impacting gross margin by ~50bps.
- METROBRA started local manufacturing of *Fila* footwear in India, and launched the first tranche of *Fila* goods in October. It plans to launch the second tranche in mid-February 2025 after successful trial.
- Fila inventory is available across Fila EBOs, Footlocker stores and 90-100 Metro/Mochi MBOs.
- ▶ *Fila's* royalty underwent restructuring Fila Global will align royalty expenses in line with revenue growth in the next 2-3 years.

BIS norms - Impact

- BIS implications remain critical for *Footlocker*'s supply chain. Green shoots are visible as several
 partner factories in South East Asia may get approval from the government. Some factories in
 Vietnam and Indonesia have already received approval.
- BIS norms have minimal impact on the core businesses (*Metro, Mochi, Walkway, Crocs*) due to local sourcing.





Exhibit 1: Store count at 895 in Q3FY25


Source: Company, Elara Securities Research

Exhibit 2: Premiumization journey continues




Source: Company, Elara Securities Research

Exhibit 3: e-commerce share on an uptrend



Source: Company, Elara Securities Research





Source: Company, Elara Securities Research

Exhibit 5: Valuation summary

(INR)	
FY27E EPS	19
Target P/E (x) - Implied	75
Target price	1,457
CMP	1,199
Upside (%)	26


Note: pricing as on 17 January 2025; Source: Elara Securities Estimate

Exhibit 6: Change in estimates

	Ne	w estimates		Ol	d estimates		C	hange (%)	
(INR mn)	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Net sales	25,086	28,853	33,736	27,187	31,923	37,666	(7.7)	(9.6)	(10.4)
EBITDA	7,551	8,829	10,391	8,238	9,768	11,601	(8.3)	(9.6)	(10.4)
EBITDAM (%)	30.1	30.6	30.8	30.3	30.6	30.8	-20 bp	0 bp	0 bp
PAT	3,557	4,369	5,293	4,482	5,452	6,828	(20.6)	(19.9)	(22.5)
EPS (INR)	13.1	16.1	19.5	16.5	20.1	25.1	(20.6)	(19.9)	(22.5)
Target price (INR)			1,457			1,873			(22.2)

Source: Elara Securities Estimate

Coverage History



	Date	Rating	Target Price	Closing Price
1	29-Aug-2024	Buy	INR 1,873	INR 1,308
2	17-Jan-2025	Buy	INR 1,457	INR 1,199

Guide to Research Rating

BUY	Absolute Return >+20%
ACCUMULATE	Absolute Return +5% to +20%
REDUCE	Absolute Return -5% to +5%
SELL	Absolute Return < -5%



Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient of in understanding / evaluating the Proposal. Nothing in this document factor boy or sell to solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document tanks such investigations as it deems necessary to arrive and an independent evaluation of an investment in the securities (India) Private Limited or any of its affiliates is committed to provide independent dur transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information in this Note and expressly disclaim all liability for any verors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information. Elara Securities (India) Private Limited or any of its affiliates have of tidependently verified all the information response to be contributed private securities (India) private Limited or any of its affiliates the recipient of the securities of company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly in any form to any rober person or published, copied, in whole or in part, for any purpose. This Note is not directed or instinuted or any of its affiliates to any registration or licensing requirements within such user juricelation, availability or use would be contrary to law, regulation

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited. Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate and compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for protects or services of ther than investment banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclosures for U.S. Investors

The research analyst did not receive compensation from Metro Brands Limited.

Elara Capital Inc.'s affiliate did not manage an offering for Metro Brands Limited.

Elara Capital Inc.'s affiliate did not receive compensation from Metro Brands Limited in the last 12 months.

Elara Capital Inc.'s affiliate does not expect to receive compensation from Metro Brands Limited in the next 3 months.

Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in a different currency to the stated date or take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.



India

Elara Securities (India) Private Limited One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500

Sales Team

Europe Elara Capital Plc. 6th Floor, The Grove, 248A Marylebone Road, London, NW1 6JZ,

Tel: +44 20 7486 9733

United Kingdom

USA Elara Securities Inc. 230 Park Avenue, Suite 2415, New York, NY 10169, USA Tel: +1 212 430 5870 Fax: +1 212 208 2501

Asia / Pacific Elara Capital (Asia) Pte.Ltd. One Marina Boulevard, Level 20, Singapore 018989 Tel : +65 6978 4047

Managing Director	Harendra Kumar harendra.kumar@elaracapital.com +91 22 6164 8571
Head of Research	Dr Bino Pathiparampil bino.pathiparampil@elaracapital.com +91 22 6164 8572

Sales realli		
🛞 India	Hitesh Danak - hitesh.danak@elaracapital.com - +91 22 6164 8543 Ashok Agarwal - ashok.agarwal@elaracapital.com - +91 22 6164 8558	
India, APAC & Australia	Sudhanshu Rajpal - sudhanshu.rajpal@elaracapital.com - +91 22 6164 8508 Joshua Saldanha - joshua.saldanha@elaracapital.com - +91 22 6164 8541 Shraddha Shrikhande - shraddha.shrikhande@elaracapital.com - +91 22 6164 8567	
India & UK	Prashin Lalvani - prashin.lalvani@elaracapital.com - +91 22 6164 8544	
India & US	Karan Rathod - karan.rathod@elaracapital.com - +91 22 6164 8570	
Corporate Access, Conference & Events	Anita Nazareth - anita.nazareth@elaracapital.com - +91 22 6164 8520 Tina D'souza - tina.dsouza@elaracapital.com - +91 22 6164 8595	

Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: <u>investor.grievances@elaracapital.com</u> - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: <u>anand.rao@elaracapial.com</u> - Tel. +91 22 6164 8509